Structural Formula (30ee4705 36a5 4a56 852d 9d76c40668db 01)
Tadalafil Tablet
Product Images NDC 70518-4605
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 70518-4605). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (30ee4705 36a5 4a56 852d 9d76c40668db 02)
Figure 2 (30ee4705 36a5 4a56 852d 9d76c40668db 03)
This text provides data on standing and supine systolic blood pressure (mmHg) at different time points post-dose for a comparison between Tadalafil 20 mg & doxazosin 8 mg and Placebo & doxazosin 8 mg.*
Figure 3 (30ee4705 36a5 4a56 852d 9d76c40668db 04)
Not Available*
Figure 4 (30ee4705 36a5 4a56 852d 9d76c40668db 05)
This text provides information on plasma tadalafil concentration in ug/L for different dosages and administration schedules. It shows data points at various time intervals after taking a single 20-mg dose of tadalafil, a single 5-mg dose, and once-daily 5-mg doses following 5 consecutive days of administration. The time intervals are marked from 0 to 120 hours.*
Figure 5 (30ee4705 36a5 4a56 852d 9d76c40668db 06)
Change from Baseline in IPSS Total Score for Tadalafil 5 mg and Placebo over a 12-week treatment duration.*
Figure 6 (30ee4705 36a5 4a56 852d 9d76c40668db 07)
Change from Baseline in IPSS Total Score in patients treated with Tadalafil 5 mg compared to Placebo over a 12-week treatment period. The statistical significance is indicated by *p<0.001.*
Figure 7 (30ee4705 36a5 4a56 852d 9d76c40668db 08)
This text appears to provide data on the LS mean change from baseline for different treatment groups at weeks 12 and 26 of therapy. The treatments compared are Tadalafil/Finasteride and Placebo/Finasteride, with significant differences indicated by the p-values. The information seems to be part of a study or analysis comparing the efficacy of these treatments over time.*
Figure 8 (30ee4705 36a5 4a56 852d 9d76c40668db 09)
This text provides information on the change from baseline in IPSS Total Score after using Tadalafil 5mg compared to Placebo over a treatment duration of 12 weeks. The statistical significance level is indicated as p<0.01, suggesting a notable difference in efficacy between the two treatments.*
Remedy_label (Remedy Label)
This text provides information about a 5mg Tadalafil tablet, with details such as NDC number, manufacturer information, dosage instructions, storage guidelines, and precautions. The medication is repackaged by RemedyRepack Inc. and manufactured by Torrent in Bharuch, India. It is recommended to keep the medication out of the reach of children and store it at a temperature between 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F).*
Mm1 (Tadalafil 5mg 70518 4605 00)
This text contains information about a Tadalafil Tablet in 5mg strength, with a quantity of 50 per box. The NDC number is 70518-4605-00. The tablet is repackaged by RemedyRepack Inc., in Indiana, PA. The manufacturing company is Torrent in Bharuch, India. The usual dosage instructions are provided in the insert. It advises to keep the medication out of reach of children and store at 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F) as per USP guidelines.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
